Tempus xF+ liquid biopsy for Life Sciences

Overview

Tempus is proud to offer one of the largest available liquid biopsy (LBx) panels on the global market. The panel interrogates 523 genes focused on oncogenic and resistance mutations in cell-free DNA (cfDNA) to help identify therapy opportunities.

Depth of sequencing (average)

DNA sequencing is performed to >5,000x and >1,500x unique coverage for enhanced and additional regions, respectively.

Platforms used

Illumina NovaSeq

 

Accepted sample types

Peripheral blood

 

Alterations identified

SNV, insertions / deletions, CNGs, gene rearrangements from select genes, MSI, bTMB

Sensitivity

98.3% for SNVs (≥ 0.2% VAF), 95.5% for indels (≥ 0.25% VAF), >99.9% for CNGs, 96.8% for rearrangements, 90% for MSI-H,78.5% for bTMB1

ctDNA tumor fraction calculation & monitoring

Measures changes in ctDNA tumor fraction to determine early response to immunotherapy for patients with advanced cancers.

 

Gene list

Download xF+ Validation

Features

Enhanced testing

 

Discover actionable alterations with complementary testing
Non-overlapping actionable gene alterations may be discovered using complementary tissue and liquid biopsies. In one study of NSCLC patients, the addition of plasma sequencing increased targetable mutation detection to 35.8% compared to 20.5% with tissue alone.2

Diagram of human torso indicating an unknown primary tumor and two metastatic sites.Diagram of human torso indicating an unknown primary tumor and two metastatic sites.

Evolutionary insight

 

Monitor disease recurrence after treatment
Longitudinal testing can help in the identification of genomic alterations predictive of response and resistance to targeted therapies and evaluation of genomic heterogeneity.

Longitudinal data chart and table illustrating gene mutation percentages over time.Longitudinal data chart and table illustrating gene mutation percentages over time.
Explore our full suite of NGS assays for every stage of clinical development ↗︎

References

  1. Tempus xF+ validation paper.
  2. In a subset of 229 NSCLC patients, tissue testing alone detected targetable mutations for 47 patients, whereas plasma sequencing increased targetable mutation detection to 82. Aggarwal C et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer. JAMA Oncol. 2019;5(2):173–180. doi:10.1001/jamaoncol.2018.4305

The information on this page is intended for life sciences companies and focuses on research and development applications.

This is AI-enabled precision medicine

This is the future of healthcare.